Vaxcyte stock
PCVXNASDAQVaxcyte, Inc., HealthcareISIN US92243G1085
46Score 46 out of 100, Weak
Price and trend
87 / 100
Price history
+50% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 19% above it.
Since November 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 7.0% below its 52-week high. Largest decline in 6 years: 76% (October 2024 to April 2025).
Chart figures for advanced users
- SMA 50$62.13
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$57.58
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$43.06
- The lowest closing price of the last twelve months.
- Resistance$73.82
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Vaxcyte, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $10.8B, is number 34 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 46 out of 100 (Weak): rank 450 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $1.56B, financial debt $228.84M.Stability 73
Weaknesses
- DilutionShare count up 361% since 2020.Capital allocation 18
- Loss-makingLoss of $766.63M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$669.29M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 45 to 46.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 23 Feb 2027in 103 days
- Last reported
- 4 Nov 2026EPS reported −$1.99 (expected −$2.11)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 8.3% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$8.07+2.0%
- Revenue
- $25M0.0%
- Earnings per share
- −$7.00−8.3%
- Revenue
- $87.15M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $10.44M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Cowan ElviaSale
2 Nov 2026, SVP, Finance & CAO
- Shares
- 3,000
- Price
- $60.92
- Value
- $182,753
- Wassil JimSale
2 Nov 2026, EVP, Chief Scientific Ofc, COO
- Shares
- 2,250
- Price
- $60.90
- Value
- $137,024
- Wassil JimSale
5 Oct 2026, EVP, Chief Scientific Ofc, COO
- Shares
- 18,000
- Price
- $86.74
- Value
- $1.56M
Show 14 more
- Cowan ElviaSale
5 Oct 2026, SVP, Finance & CAO
- Shares
- 19,000
- Price
- $86.74
- Value
- $1.65M
- Wassil JimSale
1 Oct 2026, EVP, Chief Scientific Ofc, COO
- Shares
- 2,250
- Price
- $56.67
- Value
- $127,513
- Wassil JimSale
9 Sept 2026, EVP, Chief Scientific Ofc, COO
- Shares
- 1,334
- Price
- $59.52
- Value
- $79,401
- Wassil JimSale
4 Sept 2026, EVP, Chief Scientific Ofc, COO
- Shares
- 1,381
- Price
- $61.16
- Value
- $84,462
- Wassil JimSale
1 Sept 2026, CHIEF OPERATING OFFICER
- Shares
- 3,477
- Price
- $61.07
- Value
- $212,352
- Dhaliwal Harpreet S.Sale
5 Aug 2026, Chief Technical Ops Officer
- Shares
- 17,000
- Price
- $55.00
- Value
- $935,068
- Wassil JimSale
3 Aug 2026, CHIEF OPERATING OFFICER
- Shares
- 2,250
- Price
- $53.86
- Value
- $121,195
- Guggenhime AndrewSale
3 Aug 2026, PRESIDENT AND CFO
- Shares
- 10,000
- Price
- $53.89
- Value
- $538,879
- Pickering GrantSale
27 Jul 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 18,198
- Price
- $55.63
- Value
- $1.01M
- Guggenhime AndrewSale
6 Jul 2026, PRESIDENT AND CFO
- Shares
- 10,000
- Price
- $57.28
- Value
- $572,837
- Wassil JimSale
1 Jul 2026, CHIEF OPERATING OFFICER
- Shares
- 2,250
- Price
- $56.33
- Value
- $126,736
- Pickering GrantSale
26 Jun 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 24,237
- Price
- $55.22
- Value
- $1.34M
- Pickering GrantSale
18 Jun 2026, CHIEF EXECUTIVE OFFICER
- Shares
- 23,461
- Price
- $52.50
- Value
- $1.23M
- Guggenhime AndrewSale
18 Jun 2026, PRESIDENT AND CFO
- Shares
- 10,000
- Price
- $53.00
- Value
- $530,000
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Vaxcyte
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Financière de TubizeTUB.BR $11.9B50
- Halozyme TherapeuticsHALO $11.59B80
- Bio-TechneTECH $11.44B65
- BioMarin PharmaceuticalBMRN $11.3B50
- Akeso9926.HK $10.58B32
- Sichuan Kelun Pharmaceutical002422.SZ $10.43B70
- Spyre TherapeuticsSYRE $10.14B48
- TG TherapeuticsTGTX $10.07B65
ETFs that hold Vaxcyte
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 4.33% | 0.89% | €11.61M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.60% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.39% | 0.30% | €185.82M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.31% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.31% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.16% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.07% | 0.35% | €434.1M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.07% | 0.35% | €8.19B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.